 Cardiac function may improve in patients with end-stage heart failure who receive long-term support with ventricular assist devices VAD. Reverse left ventricular remodeling may be sufficient in some cases to allow explantation of the VAD. However, some questions continue to await definitive answers. This study is designed to assess the myocardial recovery under VAD support with optimal pharmacological therapy high doses group I of statins, beta-blockers, angiotensin-converting enzyme inhibitors versus standard doses group II. 